Bonus Issues. If there is a bonus issue to the holders of CDIs, the number of CDIs representing shares of Common Stock over which the Warrant is exercisable will be increased by the number of CDIs which the Holder would have received if it had exercised the Warrant before the record date for the bonus issue.

Further Issues. The Company may, without the consent of the Noteholders, create and issue additional notes (“Additional Notes”) having the same terms and conditions of the Subordinated Notes (except that the Issue Date and the issue price may differ from the Subordinated Notes) so that the Additional Notes shall be consolidated and form a single series with the Subordinated Notes; provided, however, that no Additional Notes may be issued at a price

Escalating Issues. If Client believes the severity level of Client’s problem is insufficient, contact Relativity Client Support and request that the severity level be upgraded. If Client feels that a Severity 1 problem is not being adequately addressed, the Client should contact Relativity Vice President of Customer Success and Support at [[Phone]].

Product Issues. Supplier shall promptly notify [[OUTSET:Organization]] of any lot failure, Supplying problems or similar issues, or any issues that may impact [[OUTSET:Organization]]’s ability to distribute Products to its customers. Within ​ days after Supplier’s receipt of any response or other Notice from [[OUTSET:Organization]] that a problem has developed with a Product, Supplier shall perform a failure analysis and provide a detailed written response to [[OUTSET:Organization]] outlining a plan to resolve the problem, to the extent such problem is related to Supplier’s Supply of the Product or obligations under this Agreement.

In the event of a breach or default # under the Second Lien Intercreditor Agreement by any party thereto (other than the Administrative Agent) or # by any holder of Subordinated Indebtedness, of such subordination provisions, in each case, which circumstance is capable of being cured or mitigated by action or inaction by any of the Loan Parties, the Loan Parties shall take any practicable action or refrain from taking action available to it to cure or mitigate such breach or default.

Additional Issues. Within ​ days after the receipt of the Arbitration Request, the other Party may, by written notice, add additional issues for resolution in a statement of counter-issues.

If any ABL Secured Party is required in any Insolvency Proceeding or otherwise to turn over or otherwise pay to the estate of any Borrower or any other Grantor (or any trustee, receiver, interim receiver, monitor or similar Person therefor), because the payment of such amount was declared to be fraudulent, preferential or transaction at undervalue in any respect or for any other reason, any amount (an “ABL Recovery”), whether received as proceeds of security, enforcement of any right of setoff or otherwise, then as among the parties hereto the ABL Obligations shall be deemed to be reinstated to the extent of such ABL Recovery and to be outstanding as if such payment had not occurred, and the ABL Secured Parties shall be entitled, to the extent they are entitled hereunder, to a Discharge of ABL Obligations with respect to all such recovered amounts and shall have all rights hereunder until such time. If this Agreement shall have been terminated prior to such ABL Recovery, this Agreement shall be reinstated in full force and effect, and such prior termination shall not diminish, release, discharge, impair or otherwise affect the obligations of the parties hereto.

PMDA Issues. Both Parties confirm that there are pending inquiries, questions and requests ​ and such pending inquiries, questions, requests and issues are set forth in Exhibit E. Each Party shall use Commercially Reasonable Efforts to respond to, and address such inquiries, questions, and requests within the time period set forth in Exhibit E.

Safety Issues. The Parties will enter into a pharmacovigilance agreement (“Pharmacovigilance Agreement”), at a mutually agreed date, at least ​ days prior to ​. The Pharmacovigilance Agreement will govern the procedure for the mutual exchange of safety information within appropriate timeframes and in an appropriate format to enable the Parties to comply with any local and international regulatory reporting obligations and to facilitate appropriate safety reviews.

Other Safety Issues. At the reasonable request of either Party, the Parties shall establish a committee to handle the discussion of specific safety issues, advise each Party concerning the collection and evaluation of safety data, and respond to any significant safety issues raised, or requests made, by Regulatory Authorities.